Related Experiment Video

Updated: Mar 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis

Annelie Hellvard1,2, Lutz Zeitlmann3, Ulrich Heiser4

  • 1Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway.

Scientific Reports
|August 12, 2016
PubMed

Insights

Specific oral small-molecule inhibitors targeting cyclin-dependent kinase 9 (CDK9) effectively reduced disease severity in experimental arthritis models. This CDK9 inhibition induced apoptosis in immune cells, offering potential for treating autoimmune diseases.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Rheumatoid arthritis involves synovial inflammation and fibroblast-like synoviocyte proliferation.
  • Inducing apoptosis is a validated strategy for proliferative autoimmune diseases and experimental arthritis models.

Purpose of the Study:

  • To investigate the therapeutic potential of oral small-molecule inhibitors of cyclin-dependent kinase 9 (CDK9) in collagen-induced arthritis.
  • To analyze the effects of CDK9 inhibition on disease development, immune cell apoptosis, and molecular markers.

Main Methods:

  • DBA/1 mice were immunized with bovine collagen type II to induce arthritis.
  • Mice received oral treatment with specific CDK9 inhibitors.
  • Analysis included RNA and protein expression, apoptosis induction, caspase activation, and lymphocyte phenotype.

Main Results:

  • CDK9 inhibition significantly delayed disease onset and reduced severity in collagen-induced arthritis.
  • Inhibition of CDK9 led to decreased Mcl-1 expression and increased apoptosis in peripheral blood mononuclear cells.
  • Transient CDK9 inhibition induced apoptosis in leukocyte subsets and modulated the immune response.

Conclusions:

  • Specific oral CDK9 inhibitors demonstrate efficacy in preclinical models of arthritis.
  • CDK9 inhibition represents a potential therapeutic strategy for autoimmune and inflammatory diseases, as well as cancer.
  • Targeting CDK9 offers a novel approach to modulate immune responses through targeted apoptosis induction.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

6.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K